Matchpoint Therapeutics is a biotechnology company focused on discovering precision covalent small‑molecule medicines, initially targeting immunology. Its Advanced Covalent Exploration (ACE) platform combines proprietary chemoproteomics, machine learning, and evolving covalent compound libraries to identify and prioritize covalent binders in native cellular contexts. The company emphasizes covalent approaches to achieve durable target engagement with improved potency, selectivity, and lower systemic exposure. Matchpoint is building a discovery pipeline of covalent inhibitors, covalent degraders, and covalent molecular glues for targets otherwise unamenable to small molecules. The launch is backed by $100 million in financing to advance the ACE platform and the company's immunology-focused pipeline. The founding team includes Nathanael Gray, Edward Chouchani, Jianwei Che, and Tinghu Zhang, and Andre Turenne serves as CEO.

Total raised

$70M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2022